 Sulfonamides
"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 3 | 0 | 3 | | 2000 | 1 | 2 | 3 | | 2001 | 1 | 1 | 2 | | 2002 | 5 | 0 | 5 | | 2003 | 3 | 1 | 4 | | 2004 | 4 | 2 | 6 | | 2005 | 5 | 4 | 9 | | 2006 | 7 | 7 | 14 | | 2007 | 2 | 2 | 4 | | 2008 | 7 | 4 | 11 | | 2009 | 6 | 2 | 8 | | 2010 | 8 | 4 | 12 | | 2011 | 11 | 7 | 18 | | 2012 | 7 | 6 | 13 | | 2013 | 8 | 6 | 14 | | 2014 | 12 | 7 | 19 | | 2015 | 9 | 9 | 18 | | 2016 | 7 | 5 | 12 | | 2017 | 7 | 5 | 12 | | 2018 | 9 | 10 | 19 | | 2019 | 11 | 5 | 16 | | 2020 | 8 | 11 | 19 | | 2021 | 4 | 5 | 9 | | 2022 | 2 | 11 | 13 | | 2023 | 0 | 2 | 2 | | 2024 | 7 | 5 | 12 | | 2025 | 4 | 5 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Lachowiez CA, Heiblig M, Aspas Requena G, Tavernier-Tardy E, Dai F, Ashango AB, Peters DT, Fang J, Kaempf A, Long N, Eide CA, Kurtz SE, Xie W, Agarwal A, Sahasrabudhe A, McMahon CM, Amaya ML, Meyers G, Gandhi A, Leonard J, Hayes-Lattin B, Maziarz RT, Traer E, Cook RJ, Swords R, Braun TP, Saultz JN, Eckel AM, Loken MR, Zeidner JF, Tyner JW, Pollyea DA. Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study. Blood Cancer Discov. 2025 Sep 03; 6(5):437-449.
-
Verheye S, Ferdinande B, Bennett J, Staico R, El-Jack S, Tonino PAL, Abizaid A, Buysschaert I, Scott D, Menon M, Wilkins G, McClean D, Kovarnik T, Christians U, Neylon A, Mehmedbegovic Z, Smits PC, Morice MC, Webster M. Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus. Catheter Cardiovasc Interv. 2025 Oct; 106(4):2770-2780.
-
Venkatasubramanian R, Darrah MA, Mahoney SA, Hutton DA, Maurer GS, Ludwig KR, Van Dongen NS, Greenberg NT, Longtine AG, Brunt VE, Singh P, Galligan JJ, Trujillo MN, Kapahi P, Melov S, Rossman MJ, Seals DR, Clayton ZS. Cellular Senescence Mediates Doxorubicin Chemotherapy-Induced Aortic Stiffening: Role of Glycation Stress. Hypertension. 2025 Oct; 82(10):1767-1777.
-
Garcia JD, Wang C, Alexander RPD, Banks E, Fenton T, DeKeyser JM, Abramova TV, George AL, Ben-Shalom R, Hackos DH, Bender KJ. Differential roles of NaV1.2 and NaV1.6 in neocortical pyramidal cell excitability. Elife. 2025 Jul 15; 14.
-
Muthu Ramalingam B, Sears JD, Talbot KM, Su YN, Houliston S, Hossain MA, Davis-Gilbert ZW, Zhao C, Oh HJ, Brown PJ, Sanders MK, Moorman SR, Ojha D, Burdick JE, Law I, Morales NL, Martinez SA, Loppnau P, Garcia Perez J, Drobish AM, Morrison TE, Streblow ZJ, Streblow DN, Arrowsmith CH, Vargason A, Couñago RM, Halabelian L, Arnold JJ, Cameron CE, Moorman NJ, Heise MT, Willson TM. Identification of Direct-Acting nsP2 Helicase Inhibitors with Antialphaviral Activity. J Med Chem. 2025 Jul 24; 68(14):14514-14536.
-
Karol SE, Khaw SL, Zwaan CM, Baruchel A, Bittencourt H, Cooper TM, Flotho C, Fraser C, Forlenza CJ, Goldsmith KC, Macy ME, Morgenstern DA, O'Brien MM, Petit A, Ziegler DS, Reinhardt D, Opferman JT, Rubnitz JE, Onishi M, Dunshee DR, Dunbar F, Vishwamitra D, Ross JA, Chen X, Unnebrink K, Kammerlander M, Salem AH, Palenski TL, Sunkersett G, Place AE. Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia. Pediatr Blood Cancer. 2025 Jul; 72(7):e31714.
-
Singh M, Sarhan MO, Damiba NNL, Singh AK, Villabona-Rueda A, Nino-Meza OJ, Chen X, Masias-Leon Y, Ruiz-Gonzalez CE, Ordonez AA, D'Alessio FR, Aboagye EO, Carroll LS, Jain SK. Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. Nat Commun. 2025 Mar 27; 16(1):3003.
-
Yamazaki S, Kaneko S, Shimbo A, Irabu H, Ogino R, Miyamoto T, Izawa K, Segawa Y, Kakizaki J, Mori M, Shimizu M. Overlapping Aicardi-Goutières and Singleton-Merten syndromes with a heterozygous gain-of-function mutation in IFIH1 mimicking juvenile idiopathic arthritis. Immunol Med. 2025 Sep; 48(3):256-260.
-
Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, Engel K, Gipson S, Ransom M, Amaya M, Inguva A, Gasparetto M, Althoff MJ, Miller R, Shelton I, Tolison H, Krug A, Culp-Hill R, D'Alessandro A, Sherbenou DW, Pollyea DA, Smith C, Jordan CT. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. Haematologica. 2025 Jan 01; 110(1):103-116.
-
Lachowiez CA, Ravikumar VI, Othman J, O'Nions J, Peters DT, McMahon C, Swords R, Cook R, Saultz JN, Tyner JW, Dillon R, Zeidner JF, Pollyea DA. Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML. Blood. 2024 Dec 26; 144(26):2788-2792.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|